U.S. markets closed
  • S&P 500

    +51.87 (+1.60%)
  • Dow 30

    +358.52 (+1.34%)
  • Nasdaq

    +241.29 (+2.26%)
  • Russell 2000

    +23.09 (+1.59%)
  • Crude Oil

    -0.27 (-0.67%)
  • Gold

    -12.60 (-0.67%)
  • Silver

    -0.21 (-0.91%)

    -0.0037 (-0.31%)
  • 10-Yr Bond

    -0.0070 (-1.05%)

    -0.0007 (-0.06%)

    +0.1570 (+0.15%)

    -33.64 (-0.31%)
  • CMC Crypto 200

    +11.55 (+5.30%)
  • FTSE 100

    +19.89 (+0.34%)
  • Nikkei 225

    +116.80 (+0.51%)

Global Healthcare Nanotechnology (Nanomedicine) Industry Outlook 2020-2027 with Profiles of 46 Players Including Abbott Labs, Celgene Corp, GE Healthcare, J&J and Pfizer

DUBLIN, Aug. 5, 2020 /PRNewswire/ -- The "Healthcare Nanotechnology (Nanomedicine) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo
Research and Markets Logo

The publisher brings years of research experience to this 9th edition of the report. The 190-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Global Healthcare Nanotechnology (Nanomedicine) Market to Reach $475.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Healthcare Nanotechnology (Nanomedicine) estimated at US$183.9 Billion in the year 2020, is projected to reach a revised size of US$475.2 Billion by 2027, growing at a CAGR of 14.5% over the analysis period 2020-2027.

Therapeutics, one of the segments analyzed in the report, is projected to record a 14.1% CAGR and reach US$369.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Regenerative medicine segment is readjusted to a revised 15.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $54.3 Billion, While China is Forecast to Grow at 14% CAGR

The Healthcare Nanotechnology (Nanomedicine) market in the U.S. is estimated at US$54.3 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$82.8 Billion by the year 2027 trailing a CAGR of 14% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.8% and 12.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.7% CAGR.

In-vitro diagnostics Segment to Record 16.3% CAGR

In the global In-vitro diagnostics segment, USA, Canada, Japan, China and Europe will drive the 16.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$5.7 Billion in the year 2020 will reach a projected size of US$16.2 Billion by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$56.9 Billion by the year 2027.

Competitors identified in this market include, among others:

  • Abbott Laboratories

  • Celgene Corporation

  • CombiMatrix Corporation

  • GE Healthcare

  • Johnson & Johnson

  • Leadiant Biosciences, Inc.

  • Mallinckrodt PLC

  • Merck & Co. Inc.

  • NanoSphere Health Sciences, Inc.

  • Pfizer, Inc.

Total Companies Profiled: 46

For more information about this report visit https://www.researchandmarkets.com/r/44bvip

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


View original content:http://www.prnewswire.com/news-releases/global-healthcare-nanotechnology-nanomedicine-industry-outlook-2020-2027-with-profiles-of-46-players-including-abbott-labs-celgene-corp-ge-healthcare-jj-and-pfizer-301106574.html

SOURCE Research and Markets